New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
16:21 EDTJEF, CLVS, SRPT, TRV, TIE, JCP, GILD, NYX, LUK, GSK, UNH, PCPOn The Fly: Closing Wrap
Stocks on Wall Street finished virtually unchanged as the holiday held trading volumes down. With bond markets and banks being closed for Veterans Day the averages stayed within a narrow range on either side of the flat line... ECONOMIC EVENTS: In the U.S. no economic data was released. In Asia, China’s exports rose 11.6% in October, topping forecasts. However, Japan's gross domestic product fell an annualized 3.5% in the three months through September and economists predict the nation’s economy will shrink again in the next quarter, meaning it will have moved into recession... COMPANY NEWS: Leucadia National (LUK) agreed to acquire the remaining 71.4% of Jefferies (JEF) it doesn't own for $17.66 per share in an all stock transaction and shares of Jefferies rose $2.00, or 14.02%, to $16.27. Also, after Friday's closing bell, Precision Castparts (PCP) announced a deal to buy Titanium Metals (TIE) for $16.50 per share, or $2.9B. Shares of Titanium Metals closed up $4.93, or 42.61%, to $16.50 and shares of Precision Castparts also advanced $8.36, or 4.88%, to $179.69... The NYSE (NYX) said that it is continuing to investigate issues that affected trading in 216 symbols. Affected symbols included Dow members Travelers (TRV) and United Health Care (UNH)... MAJOR MOVERS: Among the notable gainers was Gilead (GILD), up $8.91, or 13.71%, to $73.92 after the company reported that it did not detect hepatitis C virus, or HCV, in the RNA of 25 HCV patients four weeks after they were treated with the company's investigational drug. Also higher were shares of Sarepta Therapeutics (SRPT), up $4.38, or 19.25%, to $27.13 after a JMP Securities analyst said a Duchenne muscular dystrophy treatment developed by GlaxoSmithKline (GSK) that will compete with Sarepta's drug is unlikely be approved until 2014 or 2015. Among stocks trading lower was J.C. Penney (JCP), down $2.67, or 12.94%, to $17.97 as the stock continued its downtrend after last week's earnings miss and was downgraded to Underperform from Neutral at Credit Suisse. Also lower were shares of Clovis Oncology (CLVS), down $8.99, or 41.83%, to $12.50 after the company reported negative results from a cancer drug trial and said it would suspend all development of the drug pending further evaluation of the data... INDICES: The Dow gained 1.31, or 0.01%, to 12,816.70; the Nasdaq fell 0.61, or 0.02%, to 2,904.26; and the S&P 500 added 0.15, or 0.01%, to 1,380.00.
News For JEF;LUK;TIE;PCP;NYX;TRV;UNH;GILD;SRPT;GSK;JCP;CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 13, 2015
15:15 EDTJCPJ.C. Penney May 9 straddle priced for 8.2% movement into Q1
Subscribe for More Information
15:04 EDTJCPNotable companies reporting after market close
Subscribe for More Information
13:12 EDTGILDSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
12:54 EDTJCPEarnings Watch: J.C. Penney sees Q1 SSS up 3.5%-4.5%
J.C. Penney (JCP) is scheduled to report first quarter earnings after the market close on Wednesday, May 13, with a conference call scheduled for 4:30 pm ET. J.C. Penney operates about 1,100 retail stores and jcp.com. EXPECTATIONS: Analysts are looking for a loss per share of (77c) on revenue of $2.87B, according to First Call. The consensus range for EPS is (96c)-(61c) on revenue of $2.78B-$2.92B. LAST QUARTER: J.C. Penney reported fourth adjusted earnings per share of breakeven against estimates for 11c, on revenue of $3.89B against estimates for $3.87B. Comparable store sales were up 4.4%. The company forecast fiscal year 2015 SSS up 3%-5% and said it expected gross margin to improve 50 to 100 basis points versus 2014 and free cash flow to be flat. On its Q4 earnings conference call, the company said that it expected Q1 sales to be impacted less than 1% due to the West Coast port slowdown. NEWS: On March 17, AdAge said Chief Marketing Officer Debra Berman would leave the company immediately. Later that day, Bloomberg reported that General Cousnel Janet Dhillon would also leave the company, which was confirmed by J.C. Penney on March 20. On April 28, J.C. Penney appointed Mary Beth West as executive vice president and Chief Customer & Marketing Officer, effective June 1. In an April regulatory filing, J.C. Penney said it became aware that a senior company official "inadvertently sent an e-mail communication to a securities analyst that contained non-public information regarding the company’s comparable store sales results for Q1 to date, which are approximately 6%." The company said it expects Q1 SSS up 3.5%-4.5%, which takes into account the shift of Easter into March. The retailer said it would introduce Sephora to 25 additional stores starting on May 1. In April, New York Attorney General Eric Schneiderman sent letters warning J.C. Penney and other retailers that he believes the chains are using on-call scheduling and that such practices may be in violation of New York laws. STREET RESEARCH: Following the release of J.C. Penney's Q4 results, Deutsche Bank said J.C. Penney remained a "show me story" until liquidity is improved. Craig-Hallum said J.C. Penney's 2015 gross margin outlook supports its view the company's 2017 financial targets are "unattainable." In March, JPMorgan raised its price target for the retailer to $10 from $8 and said management expressed confidence in the company’s ability to reach its 2017 EBITDA target of $1.2B. Baird said J.C. Penney's business is on "more stable footing," but believes meaningful free cash flow growth will be challenging. PRICE ACTION: Over the last three months, J.C. Penney shares are up over 7.45%. In early afternoon trading ahead of Wednesday's Q1 report, J. C. Penney is down 2.5% to $8.66.
11:38 EDTGSKGlaxoSmithKline downgraded to Neutral from Buy at UBS
Subscribe for More Information
07:31 EDTGILDHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
05:42 EDTPCPPrecision Castparts sees FY16 EPS $12.50-$13.40, consensus $13.39
Subscribe for More Information
05:41 EDTPCPPrecision Castparts reports Q4 adjusted EPS $2.94, consensus $2.97
Subscribe for More Information
05:40 EDTPCPPrecision Castparts approves $2B expansion to share repurchase program
Subscribe for More Information
May 12, 2015
16:01 EDTJCPOptions Update; May 12, 2015
Subscribe for More Information
15:00 EDTPCPNotable companies reporting before tomorrow's open
Subscribe for More Information
11:37 EDTJCPStocks with call strike movement; TWTR JCP
Subscribe for More Information
08:08 EDTCLVSClovis has a conference call hosted by JPMorgan
Subscribe for More Information
06:02 EDTGSKGSK CEO cites 'poor choices' in rivals' M&A deals, Financial Times reports
Subscribe for More Information
May 11, 2015
16:00 EDTJCPOptions Update; May 11, 2015
Subscribe for More Information
15:54 EDTGSKGlaxo CEO defends strategy, warns of risks of chasing higher prices, FT says
GlaxoSmithKline (GSK) CEO Andrew Witty defends the company's shift in focus from high-priced prescription drugs to higher volume, but lower priced, products, warning that chasing ever-higher prices risks undermining the industry and may create "its own tension that leads to some kind of change,” reported Financial Times, citing an interview. Witty acknowledges the company's asset swap with Novartis (NVS) opens the door to a potential break up, but argues there are benefits to keeping pharmaceuticals, vaccines and consumer goods together and there would be “no logic” in a split at this early time after the Novartis deal, the report added. Reference Link
07:40 EDTUNHFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertex’s Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasn’t announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
07:13 EDTUNHUnitedHealth management to meet with UBS
Subscribe for More Information
05:58 EDTGSKUNC, GlaxoSmithKline create dedicated HIV Cure center
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use